ホーム>>Signaling Pathways>> Neuroscience>> Muscarinic Receptor>>Guvacoline (hydrobromide)

Guvacoline (hydrobromide) (Synonyms: Norarecoline)

カタログ番号GC15845

心房および回腸ムスカリン受容体の完全アゴニスト

Products are for research use only. Not for human use. We do not sell to patients.

Guvacoline (hydrobromide) 化学構造

Cas No.: 17210-51-4

サイズ 価格 在庫数 個数
1mg
$63.00
在庫あり
5mg
$226.00
在庫あり
10mg
$421.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Target: atrial and ileal muscarinic receptors

IC50: 2.1 mM for growth inhibition of human buccal epithelial cells

Guvacoline is a kind of natural alkaloid which is found in areca nuts that is related to the nootropic, arecoline. Guvacoline can function as a full agonist of atrial and ileal muscarinic receptors.

In Vitro: In human buccal epithelial cells, Guvacoline could significantly decrease the colony-formation efficiency in a dose dependent manner, with the IC50 value of 2.1 mM. Besides, Guvacoline could also dose-dependently reduce the amount of total free low-molecular-weight thiols (0.88 mM Guvacoline caused 25% decrease) and increase the number of single strand breaks [1].

In Vivo: No data available recently.

Clinical trial: No data available recently.

Reference:
[1] K.  Sundqvist, Y. Liu, J. Nair, et al. Cytotoxic and genotoxic effects of areca nut-related compounds in cultured human buccal epithelial cells. Cancer Research 49(19), 5294-5298 (1989).

レビュー

Review for Guvacoline (hydrobromide)

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Guvacoline (hydrobromide)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.